On April 1, 2026, Inovio Pharmaceuticals, Inc. terminated its sales agreement for offering common stock through Oppenheimer & Co. Inc., having previously sold 1,319,644 shares for $3.2 million. No new stock sales will occur until a new prospectus is filed.